Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Clinical trial NCT00783367 · COMPLETED

Trial details

NCT number: NCT00783367
Sponsor: Abramson Cancer Center at Penn Medicine
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Follicular Lymphoma Marginal Zone B-Cell Lymphoma MALT Lymphoma Lymphoma of Mucosa-Associated Lymphoid Tissue Lymphoma, Small Lymphocytic Waldenstrom Macroglobulinemia Mantle-Cell Lymphoma

Start date: 2008-07-01
Primary completion: 2012-11-14
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.